sale growth led oncolog human health vaccin busi
maintain buy rate maintain tp
deriv tp base estim ep
forward look price-to-earnings give upsid
potenti estim
revenu growth
estim base follow factor strong
growth revenu earn strong growth china
strong growth oncolog human health vaccin
busi acquisit develop pipelin
merck sale quarter increas
driven oncolog human health vaccin human health
vaccin sale grew exclud impact
foreign exchang sale grew quarter
keytruda revenu increas
increas increas
revenu driven volum growth compani
continu launch keytruda multipl new indic
sale repres total sale
repres total sale led growth
strong perform china
net incom increas
increas non-gaap net incom
gaap ep increas increas
non-gaap ep
compani namemerck compani inc tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth merck compani inc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
bridion revenu increas
increas
increas sale mainli due volum growth
global sale perform
merck announc fda accept review six
supplement biolog licens applic sbla
updat dose frequenc keytruda includ
everi six-week dose schedul option certain
monotherapi indic fda set pdufa date
merck astrazeneca announc approv lynparza
japan separ european union use first-
line mainten therapi patient brca-mut
advanc ovarian cancer base result phase
trial lynparza parp inhibitor approv
indic parp inhibitor approv
merck expect ep rang
reflect charg relat acquisit
rang includ slightli
neg impact foreign exchang
current price-to-earnings trade
averag price-to-earnings avg-
price-to-earnings trade averag price-to-earnings
went
expect forward price-to-earnings multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date oct ex-dividend date sep last split factor new per last split date feb inform merck compani inc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur merger acquisition- total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual annual actual quarterli merck compani inc octob
equival short term invest total st invest receivablesaccount receiv receiv total receiv current assetsinventori defer tax asset current current asset total current asset long-term assetsgross properti plant equip accumul depreci properti plant equip long-term invest goodwil intang defer tax asset long-term asset total asset current liabilitiesaccount payabl accru expens short-term borrow current portion lt debt current incom tax payabl current liabil total current liabil long-term liabilitieslong-term debt pension post-retir benefit def tax liabil non-curr non-curr liabil total liabil common equitycommon stock addit paid capit retain earn treasuri stock incom common equiti stockhold equityminor interest total equiti liabil equitytot liabil equiti balanc sheet itemsactu annual actual quarterli merck compani inc octob
provid oper activ compar oper
activ reflect receipt astrazeneca relat conclus compani relationship
astrazeneca lp well tax payment option payment eisai
use invest activ compar cash provid invest activ
chang due acquisit antelliq lower proce sale secur
invest higher capit expenditur partial off-set lower purchas secur invest
well mileston payment relat collabor bayer
use financ activ compar lower use cash
financ activ driven primarili proce issuanc debt lower payment debt partial
off-set repay short-term borrow higher dividend paid sharehold higher purchas
net incom oper activ depreci amort amort goodwil intang depreci amort total loss sale asset loss sale invest asset write-down restruc cost stock-bas compens oper activ chang account receiv chang inventori chang account payabl chang incom tax chang net oper asset oper invest activ capit expenditur acquisit divestitur sale purchas intang asset invest market equiti securt invest activ invest financ activ short term debt issu long-term debt issu total debt issu short term debt repaid long-term debt repaid total debt repaid issuanc common stock repurchas common stock common prefer stock dividend paid financ activ financ chang equival foreign exchang rate adjust net chang merck compani inc octob
merck revenu increas y/i led human health busi
increas anim health increas
total sale increas compar
due strong growth oncolog human health
vaccin busi increas sale includ unfavour effect
sale repres total sale perform
intern market led china total sale
repres growth rate compar
foreign exchang unfavor affect sale perform china
gaap sale remain rel flat
compar cost includ
compar relat amort intang asset
record connect busi acquisit expens
amort amount capit connect collabor reduc
compar
sale includ catch-up amort accrual sales-bas
mileston deem compani probabl period
addit relat market product
intang record connect busi acquisit also cost
sale includ expens associ restructur activ
amount includ acceler depreci asset
write-off relat plan sale closur manufactur facil
non-gaap sale cost reflect
expens amort intang asset recogn result
busi acquisit well intang asset impair charg
total sale increas
compar
gaap sale
compar
gross margin compar
increas gross margin driven lower acquisition- divestiture-
relat cost favor product mix lower amort intang
asset relat collabor partial off-set higher restructur cost
gross margin
compar
sg expens increas compar
increas reflect higher administr cost
acquisit divestiture-rel cost restructur cost promot
cost partial off-set favor effect foreign exchang non-gaap
sg expens
gaap ep increas
compar
 expens decreas compar
decreas primarili due lower expens
busi develop transact reflect charg
relat acquisit viralyt limit viralyt
decreas expens partial off-set higher expens
relat clinic develop increas invest discoveri research
earli drug develop non-gaap expens
compar restructur cost decreas
compar
net expens compar net incom
non-gaap net incom
compar non-gaap net incom expens
reflect goodwil impair charg relat certain busi
segment expens relat increas
estim fair valu liabil contin consider relat
termin sanofi-pasteur msd joint ventur
effect incom tax rate compar
net incom increas compar
non-gaap net incom
compar ep increas
compar non-gaap ep compar
total sale increas compar
includ unfavour effect foreign
exchang increas sale primarili driven higher sale
oncolog franchis reflect strong growth keytruda well
increas allianc revenu lynparza lenvima higher sale
vaccin includ human papillomaviru vaccin gardasil pediatr
vaccin proquad m-m-r varivax also drove sale growth
sale repres total sale perform
intern market led china total sale
repres growth rate compar foreign
exchang unfavor affect sale perform china
gaap sale decreas compar
cost includ compar
relat amort intang asset record
connect busi acquisit expens amort
amount capit connect collabor increas
compar
total sale increas
compar
gaap sale
decreas
compar
sale includ catch-up amort accrual sales-bas
mileston deem compani probabl period
addit relat market product
intang record connect busi acquisit also cost sale
includ expens associ restructur activ amount
includ acceler depreci asset write-off
relat plan sale closur manufactur facil
non-gaap sale cost includ
expens amort intang asset recogn
result busi acquisit well intang asset impair
gross margin
compar
decreas
compar
gross margin compar
gross margin improv larg reflect lower aggreg impact
amort intang asset relat busi acquisit
restructur cost unfavor affect compar
gross margin improv also reflect favor
effect product mix lower amort capit mileston
payment relat collabor
sg expens increas compar
increas driven higher administr cost
restructur cost acquisit divestiture-rel cost partial
off-set favor effect foreign exchang lower sell
promot cost sg expens includ restructur cost
relat primari acceler depreci facil close
 expens decreas compar
decreas primarili driven charg
record relat format oncolog collabor
eisai lower expens relat busi develop transact
year-to-d declin also reflect favor effect foreign exchang
reduct expens relat decreas estim fair valu
measur liabil conting consider
decreas expens partial off-set higher expens
relat clinic develop increas invest discoveri research
earli drug develop non-gaap expens
compar increas primarili reflect
reduct expens relat decreas estim fair valu
measur liabil conting consider
restructur cost decreas compar
decreas includ separ cost actual
headcount reduct well estim expens exist sever
program headcount reduct probabl could
net expens compar net incom
non-gaap net incom
compar non-gaap net incom expens
reflect increas estim fair valu measur liabil
conting consider partial off-set royalti incom relat
termin sanofi-pasteur msd joint ventur
effect incom tax rate compar
decreas tax rate reflect impact acquisit
divestiture-rel cost restructur cost partial off-set
benefici impact foreign earn addit decreas also reflect
favor impact net tax benefit relat settlement
net incom increas compar
non-gaap net incom compar
ep increas compar
non-gaap ep compar
merck two busi segment pharmaceut anim health
segment consist human health vaccin
product health product pharmaceut product consist
therapeut prevent agent gener sold prescript
treatment human disord
pharmaceut segment revenu increas
compar increas
compar
gaap ep increas
compar
increas
increas
total revenu pharmaceut segment increas
compar increas
compar total
intern revenu increas compar
increas
compar
keytruda revenu increas compar
increas
compar increas revenu driven
volum growth compani continu launch keytruda multipl
keytruda revenu increas
compar increas
compar sale unit state
continu build across multipl approv indic particular
treatment nsclc monotherapi combin
chemotherapi either nonsquam squamou nsclc
indic contribut sale growth includ hnscc bladder cancer
melanoma msi-h cancer along uptak recent launch
renal cell carcinoma adjuv melanoma indic
total intern revenu keytruda increas
compar increas
compar growth
intern revenu driven use treatment nsclc
monotherapi well combin chemotherapi
indic continu launch multipl market includ europ
launch multipl new indic japan china also drove growth
increas
increas
keytruda revenu
 increas
increas
emend revenu decreas compar
decreas
compar decreas emend revenu
due lower demand unit state due competit foreign
exchang unfavor affect global sale perform
merck record allianc revenu relat lynparza
compar revenu
compar increas allianc
revenu reflect part uptak treatment ovarian cancer
follow approv decemb base phase
merck record allianc revenu compar
respect relat lenvima allianc revenu
lenvima lenvima sale reflect strong
perform hepatocellular carcinoma follow recent world-wide
gardasil revenu increas compar
increas revenu due higher demand
price unit state on-going launch china higher
demand europ reflect increas vaccin rate boy
gardasil revenu increas compar
due higher volum china unit state
europ increas includ unfavor effect foreign
gardasil revenu increas
compar increas
compar
decreas
compar
increas
increas
increas
increas
increas
increas
gardasil intern revenu increas
compar increas
compar
proquad/m-m-r ii /varivax revenu increas
compar increas
compar increas revenu
proquad driven higher volum price unit state
volum growth certain european market increas revenu
m-m-r ii driven higher sale unit state reflect
increas demand due measl outbreak includ privat sector buy-
well higher price increas revenu varivax due
govern tender brazil well volum growth price
world-wide sale rotateq
compar period sale growth
period driven primarili continu uptak launch
china
bridion revenu increas compar
increas
compar increas sale due
volum growth unit state
bridion revenu increas
compar increas
compar total intern revenu
increas compar
increas compar
noxafil revenu increas compar
increas compar
invanz revenu decreas compar
decreas
compar decreas sale due
gener competit unit state
total revenu remicad decreas
compar decreas
compar
total revenu simponi decreas
compar decreas
compar
total revenu isentress isentress hd declin
compar decreas
compar
decreas sale due lower demand unit state due
total revenu decreas
compar decreas
compar revenu
decreas compar
decreas compar
total combin revenu zetia vytorin atozet decreas
decreas
compar
total revenu
remicad decreas
decreas
zetia vytorin
atozet decreas
decreas
decreas combin sale due lower sale europ eu
patent ezetrol inegi expir april april
respect accordingli compani experienc sale declin
market result gener competit expect declin
continu merck lost market exclus unit state zetia
vytorin lost nearli sale product
result gener competit sale declin also attribut
loss exclus australia declin partial off-set
launch rosuzet japan foreign exchang unfavor affect global
sale perform
revenu adempa includ sale merck market territori
well merck share profit sale adempa bayer
market territori merck record revenu relat adempa
increas
respect compar period
total revenu
januvia janumet
decreas
decreas
decreas
compar
total revenu januvia janumet decreas
compar decreas
compar decreas revenu
reflect continu price pressur unit state partial off-set
singulair revenu decreas compar
decreas
compar
nasonex revenu declin compar
decreas
compar
total revenu nuvar increas
compar increas
compar increas includ unfavor
effect foreign exchang
total revenu anim health product increas
compar increas driven
higher sale livestock product predominantli due product obtain
antelliq acquisit
total revenu remain rel flat compar
sale perform driven livestock product due
antelliq acquisit higher demand poultri product well
higher demand companion anim product primarili bravecto line
product
total revenu livestock increas
compar remain rel flat
compar
total revenu increas
compar increas
compar revenu
remain flat compar
decreas compar
total revenu
increas
compar
total revenu
livestock increas
remain flat
merck announc
european medicin
posit opinion
keytruda
combin
axitinib first-lin
treatment advanc
rcc base
find pivot
total revenu companion anim
compar
compar decreas revenu reflect
volum growth vaccin insulin product partial off-set
time custom purchas prior year bravecto line
product parasit control
merck continu advanc develop program keytruda
pembrolizumab compani therapi lynparza olaparib
parp inhibitor co-develop co-commerci astrazeneca
lenvima lenvatinib mesyl oral avail tyrosin kinas inhibitor
co-develop co-commerci eisai co ltd eisai
merck announc food drug administr fda
approv keytruda follow indic
first-lin treatment patient metastat unresect
recurr head neck squamou cell carcinoma hnscc
monotherapi patient whose tumor express combin
posit score combin platinum
fluorouracil fu commonli use chemotherapi regimen base
overal surviv result trial
treatment patient metastat small cell lung cancer sclc
diseas progress platinum-bas chemotherapi
least one prior line therapi base result
trial
merck announc european medicin agenc ema adopt
posit opinion keytruda combin axitinib first-lin
treatment advanc renal cell carcinoma rcc base find
pivot trial
merck announc fda accept review six supplement
biolog licens applic sbla updat dose frequenc
keytruda includ everysix-week dose schedul option
certain monotherapi indic fda set pdufa date feb
merck present five-year surviv data keytruda advanc non-
small cell lung cancer nsclc first keynot trial phase
updat overal surviv analysi new data
diseas progress next-lin treatment progression-fre
trial metastat nonsquam nsclc
american societi clinic oncolog annual meet
merck announc phase trial investig
keytruda combin chemotherapi met primari endpoint
patholog complet respons pcr follow neoadjuv part
neoadjuvant/adjuv studi regimen patient triple-
neg breast cancer tnbc trial continu evalu
dualprimari endpoint event-fre surviv ef result
present upcom medic congress
merck astrazeneca announc approv lynparza japan
separ european union use first-lin mainten therapi
patient brca-mut advanc ovarian cancer base
result phase trial lynparza parp inhibitor
approv indic parp inhibitor approv japan
merck astrazeneca
present result
phase polo trial
patient germlin
progress
merck astrazeneca present result phase polo trial
patient germlin brca-mut metastat pancreat cancer whose
diseas progress follow platinum-bas chemotherapi
trial lynparza reduc risk diseas progress death
nearli half result present annual
meet simultan publish new england journal
merck astrazeneca also present result phase
trial annual meet studi evalu object
respons rate lynparza compar chemotherapi patient
cancer receiv two prior line chemotherapi
merck eisai announc receipt breakthrough therapi
design fda keytruda plu lenvima combin
regimen potenti first-lin treatment patient advanc
unresect hepatocellular carcinoma amen locoregion
treatment repres third design
merck announc center diseas control prevent
cdc advisori committe immun practic acip vote
recommend human papillomaviru hpv vaccin gardasil
human papillomaviru vaccin recombin base share
clinic decis make individu age
adequ vaccin acip also vote expand routin catch-
recommend male age adequ
merck announc
 cdss acip vote
vaccin
gardasil base
make individu
age
adequ
merck present phase trial result compani
investig pneumococc conjug vaccin
demonstr noninferior pcv share serotyp
immun respons two addit disease-caus serotyp
healthi infant result present european societi
paediatr infecti diseas espid current phase
merck present late-break data islatravir formerli
compani investig nucleosid revers transcriptas
transloc inhibitor nrtti develop prevent
treatment infect recent aid societi
confer hiv scienc ia includ
phase result demonstr combin islatravir
doravirin maintain antivir activ treatment-nav adult
week base result compani plan
initi phase program evalu islatravir combin
phase result evalu pharmacokinet safeti
prototyp subderm drug-elut implant extend
administr islatravir healthi volunt hiv pre-
merck announc fda approv expand use zerbaxa
ceftolozan tazobactam treatment adult hospital-
acquir ventilator-associ bacteri pneumonia habp/vabp
separ announc ema adopt posit opinion recommend
zerbaxa habp vabp consider
approv recabrio
treatment
adult complic
urinari tract
infect limit
altern
treatment option
merck announc fda approv recarbrio imipenem cilastatin
relebactam treatment adult complic urinari tract
complic intra-abdomin bacteri infect limit
altern treatment option avail
compani focus develop novel small molecul therapeut
candid target hypoxia-induc treatment
patient cancer non-oncolog diseas includ novel
oral inhibitor late-stag develop rcc acquisit
close juli
merck acquir gain portfolio investig
antibodi target tgf potenti applic treatment
cancer fibrosi autoimmun diseas acquisit close june
merck acquir immun design provid potenti next-gener
vivo approach enabl bodi immun system fight diseas
acquisit close april
portfolio
potenti
applic
treatment cancer
fibrosi autoimmun
revenu
impact foreign
guidanc conclus
merck expect revenu
includ neg impact foreign exchang mid-juli
ep expect
reduct ep rang primarili reflect inclus
approxim charg relat acquisit peloton
non-gaap ep expect includ
slightli neg impact foreign exchang mid-juli exchang
effect tax rate expect non-
tax rate
total sale increas compar
growth led human health anim
keytruda sale increas driven increas
adopt global first-lin lung set well uptak recent
approv indic human health vaccin sale grew
exclud impact foreign exchang sale grew
anim revenu increas livestock grew
primarili due contribut product acquir
antelliq acquisit companion anim sale grew
volum growth vaccin insulin product partial off-set
time custom purchas bravecto
keytruda combin chemotherapi primari endpoint
patholog complet respons pcr pivot phase trial
neoadjuv therapi patient triple-neg breast cancer
merck remain confid innov product signific
pipelin opportun continu deliv strong result provid
sustain valu patient sharehold merck return
sharehold dividend share repurchas
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin ttm basi decreas compar
revenu growth ttm basi increas compar
oper margin ttm basi increas compar
ep growth ttm basi increas compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck compani inc octob
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale merck compani inc octob
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn equiti merck compani inc octob
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net net margin annual itemsquarterli item merck compani inc octob
balanc sheet item
outstand equival market debt common purchas properti plant purchas sale purchas sale repurchas net issuanc net chang capit free merck compani inc octob
current price-to-earnings trade averag price-to-earnings avg-
price-to-earnings trade averag price-to-earnings went
price-to-earnings increas due increas stock price trade around
expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit world wellington manag compani america jp morgan geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard washington mutual investor incom fund america spdr etf vanguard institut fund-institut fidel ishar american balanc vanguard specialized-health fund merck compani inc octob
developmentsmerck keytruda approv monotherapi china first-lin treatment certain patient advanc non-smal cell lung cancer whose tumor octob announc keytruda merck therapi approv nation medic product administr nmpa china monotherapi first-lin treatment patient local advanc metastat non-smal cell lung cancer nsclc whose tumor express express determin nmpa-approv test egfr genom tumor aberr new indic grant full approv base overal surviv find phase trial includ data extens global studi chines patient keytruda first therapi approv china monotherapi combin chemotherapi first-lin treatment appropri patient nsclc fda accept applic merck dificid treat children age month year clostridium difficil infect octob announc food drug administr fda accept review new drug applic nda dificid oral suspens treatment clostridium difficil infect cdi children age six month order applic receiv prioriti review classif fda prescript drug user fee act target action date applic set jan investig pediatr indic dificid grant orphan drug design restore-imi phase studi merck recarbrio hospital-acquir ventilator-associ bacteri pneumonia habp/vabp primari endpoint septemb announc pivot phase recarbrio imipenem mg cilastatin mg relebactam mg restore-imi trial met primari endpoint global multicent random non-inferior trial investig efficaci safeti merck antibacteri product recarbrio use adult patient hospital-acquir bacteri pneumonia ventilator-associ bacteri pneumonia habp/vabp merck keytruda chemotherapi show staistic signific increas patholog complet respons versu chemotherapi neoadjuv therapi early-stag triple-neg breast cancer septemb announc result pivot neoadjuvant/adjuv phase trial patient wit early-stag triple-neg breast cancer tnbc trial investig regimen neoadjuv keytruda merck therapi plu chemotherapi follow adjuv truda monotherapi compar regimen neoadjuv chemotherapi follow adjuv placebo interim find first random trial therapi neoadjuvant/adjuv set tnbc present today presidenti symposium european societi medic oncolog congress merck compani inc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vs
price-to-earnings ratio ttm
industri averag
gross margin ttm
industri averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck compani inc octob
consensu view analyst trend stock
forecast
higher
compar
forward price-to-earnings
lower
mrk avgfive-year growth forecast usdgrowth high day day day estim comparisonmrkindustri avg avgprice/earn yield merck compani inc octob
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr surprisescurr growth rate merck compani inc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
merck stock price volatil quarter dip septemb
merck gave return quarter
stock price upward trend year increas
price dip march april current trade
stock show upward trend result surg time high past
stock given return past year
merck perform driven oncolog human health vaccin busi keytruda sale
grew maintain buy rate stock tp
base forward price-to-earnings multipl non-gaap estim ep expect
revenu grow
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
